Navigation Links
PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Date:4/14/2009

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
3. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
4. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
5. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
6. Study Shows Machine Perfusion Significantly Improves Transplant Results
7. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
8. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
9. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... Texas (PRWEB) , ... July 03, 2015 , ... ... firm, highly-regarded by Fortune 500 companies and professional service industries alike-- typically known ... to make clients laugh, honor a good cause and break from their day ...
(Date:7/3/2015)... Forskere kan ansøge ... http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab for Open ... Wien .  ... og videnskabsmænd foretaget af Ludwig Boltzmann Gesellschaft ... sundhedsvidenskaben manglen på incitamenter til at undersøge ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Sleepless nights will ... individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers and ... command technology makes it effortless to use, while the integration of the Bluetooth speaker, ...
(Date:7/1/2015)... ... 2015 , ... The next-generation sequencing (NGS) clinical market is poised for huge ... industry. BCC Research reveals in its new report that the market drivers of this ... growing need for better diagnostics as part of a molecular diagnostics trend. , The ...
Breaking Biology Technology:The Alexander Group Declares Their Independence with a Bit of Levity 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3
... - Strengthened Balance Sheet and Advancing Products in 2008 - ... 11:00 a.m. Eastern Time -, BRANFORD, Conn., Jan. 31 ... financial results for the,fourth quarter and fiscal year ended December ... the fourth quarter of 2007,of $11.0 million, or $0.20 per ...
... (Euronext: AMT), a leader in the field of ... plan of rotation to appoint independent,directors to its ... Mr. Philippe van Holle, Head of Celgene Europe ... of shareholders. Mr. Van Holle is expected to,replace ...
... FRANCISCO, Calif., Jan. 30 Monogram,Biosciences, Inc., (Nasdaq: ... on Thursday, February 7, 2008 at 4:30 p.m. (Eastern ... discuss the outlook for 2008.,The call will be hosted ... To participate in the live teleconference, please call ...
Cached Biology Technology:CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 2CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 3CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 4CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 5CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 6CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 7Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board 2Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board 3Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call 2
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, a ... authentication solutions, today announced enhanced functionality of its ... solution.  The enhancements build on the native ... DigitalPersona Altus platform and provide expanded mobile ... In today,s environment of increasing cyber-attacks ...
(Date:6/17/2015)... Maryland , and HILDEN, Germany , ... QGEN ; Frankfurt Prime Standard: QIA) today launched new ... evidence in forensic laboratories in the United States ... solution to simultaneously analyze multiple key genomic markers (short tandem ... ® Quality Sensor to evaluate the quality of DNA ...
(Date:6/16/2015)... , June 16, 2015  With the increasing ... security remains a top concern. The recent compromise of ... the need for strong authentication within government agencies. ... a biometric one-time password (OTP) authenticator, has been submitted ... (FIPS) 140-2 Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... developed a method to dramatically improve the longevity of ... motion of a single molecule as it travels through ... process called resonance energy transfer, which occurs when fluorescent ... will be reported at the 234th annual national American ...
... Staph Infections in Humans Including MRSA ... against Staphylococcus aureus, including methicillin-resistant strains, in mice ... in the August 2007 issue of the journal ... a highly flexible and potentially dangerous pathogen capable ...
... study in the August 21st issue of Current Biology, a ... evidence in support of the long-held notion that men and ... the researchers found that women really do prefer pinkor at ... we expected to find sex differences, we were surprised at ...
Cached Biology News:Clemson scientists shed light on molecules in living cells 2Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Girls prefer pink, or at least a redder shade of blue 2